WFH/X
Jul 29, 2025, 13:12
AAV Gene Therapies for Hemophilia A and B: Current Perspectives
The World Federation of Haemophilia (WFH) shared a proud post on X:
“Gene Therapy is transforming Hemophilia care. A new review highlights how AAV-based treatments for hemophilia A and B are delivering long-term results—some lasting years with just one dose. Challenges remain, but the future is promising.
Read more.”
Title: Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Authors: Roland W. Herzog, Radoslaw Kaczmarek, Katherine A. High
Stay informed with Hemostasis Today.
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage
-
Feb 23, 2026, 11:29Emma Lefrancais: Uncovering A Key Role for The IL-33/ST2 Axis in Platelet Biology with Lucie Gelon